Hui (David) Shao | Chief Financial Officer
Yisheng Biopharma

Hui (David) Shao, Chief Financial Officer, Yisheng Biopharma

Dr. David Shao is CFO of Yisheng Biopharma Co., Ltd.  a multinational vaccine company with business focus in China, USA and Sinbgapore.   Dr. Shao has over 15 years of experience in US biopharmaceutical and capital.  He was the former CFO of Aoxing Pharmaceutical (NYSE Listed), a Senior Healthcare Analyst and fund manager at Mehta Partners and Kamunting Street Capital in New York, a Principal Scientist at Roche Pharma, USA.  Dr. Shao received his Ph.D. at University of California, San Diego and MBA at Stern School of Business in New York University.


Day Two 11th October, Human @ 09:10

Plenary discussion: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia

  • The role of emerging markets in the global supply and demand for vaccines
  • What vaccine technologies and vaccine candidates are favourable?
  • Does it align with other philanthropy organisations?
  • The role of Public-Public Partnerships (P2Ps) in vaccine R&D for poverty related and neglected diseases (PRNDs)
  • Priorities for linking new vaccine development with public health in low and middle income countries

back to speakers